6848.TWO RBC Bioscience Corporation
- Market cap
- TWD 272M
- P/E
- 14.0x
- P/B
- 1.10x
- ROE
- 17.2%
- Dividend yield
- 4.77%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2025.
Is 6848.TWO undervalued?
Graham number6848.TWO trades 17.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RBC Bioscience Corporation fundamental analysis
No fundamental analysis for RBC Bioscience Corporation yet.
RBC Bioscience Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RBC Bioscience Corporation
RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis. It offers robotic bench-top workstation for nucleic acid purification under the MagCore Plus II and Giga Automated Nucleic Acid Extractor names; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore EDA Automatic Extraction and Smart PCR Setup, an instrument for nucleic acid extraction and PCR setup pre-t…
Full company profileRBC Bioscience Corporation financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
RBC Bioscience Corporation annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 162M | 575M | 251M | 174M | 172M | 205M | 431M |
| Gross Profit | 66.9M | 300M | 117M | 73.0M | 72.9M | 98.1M | 202M |
| Operating Income | 19.5M | 188M | 48.6M | 7.75M | 14.5M | 35.8M | 74.0M |
| EBITDA | 24.9M | 193M | 62.3M | 32.1M | 36.5M | 54.8M | 102M |
| Net Income | 14.5M | 142M | 28.7M | 3.78M | 6.43M | 21.6M | 44.7M |
| EPS | 1.76 | 12 | 2.34 | 0.29 | 0.49 | 1.65 | 3.13 |
| Balance Sheet | |||||||
| Total Assets | 201M | 513M | 848M | 791M | 754M | 764M | 726M |
| Total Liabilities | 27.2M | 338M | 591M | 542M | 513M | 515M | 466M |
| Shareholders' Equity | 87.7M | 175M | 257M | 249M | 241M | 249M | 260M |
| Cash & Short-term Investments | 43.3M | 184M | 126M | 76.6M | 65.2M | 81.1M | 43.2M |
| Total Debt | 94.8M | 120M | 511M | 482M | 472M | 478M | - |
| Cash Flow | |||||||
| Operating Cash Flow | 40.2M | 206M | -25.3M | 6.60M | 13.2M | 55.9M | 32.1M |
| Capital Expenditure | 9.08M | 118M | 450M | 10.0M | 6.46M | 10.3M | 35.2M |
| Free Cash Flow | 31.1M | 87.3M | -475M | -3.44M | 6.74M | 45.6M | -3.05M |
| Ratios | |||||||
| ROE | 16.5% | 81.2% | 11.2% | 1.5% | 2.7% | 8.7% | 17.2% |
| ROA | 7.2% | 27.7% | 3.4% | 0.5% | 0.9% | 2.8% | 6.2% |
| Net Profit Margin | 8.9% | 24.7% | 11.4% | 2.2% | 3.7% | 10.5% | 10.4% |
| Debt to Equity | 1.08x | 0.69x | 1.99x | 1.94x | 1.96x | 1.92x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
RBC Bioscience Corporation dividends
- Dividend yield
- 4.77%
- Forward dividend
- 4.73 TWD
- Payout ratio
- 60.2%
- Ex-dividend date
- Sep 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | TWD 13.0M | 0.99 | 60.2% |
| 2023 | TWD 14.5M | 1.12 | 226.0% |
| 2022 | TWD 11.8M | 0.91 | 312.2% |
| 2021 | TWD 14.4M | 1.17 | 50.1% |
| 2020 | 54.8M | 4.55 | 38.6% |
| 2019 | 12.3M | 1.49 | 84.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1100:1000 on Aug 11, 2025.
Who owns RBC Bioscience Corporation
Ownership data of RBC Bioscience Corporation is not available yet.
RBC Bioscience Corporation company profile
- Company name
- RBC Bioscience Corporation
- Ticker
- 6848.TWO
- ISIN
- TW0006848005
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 50
- Fiscal year end
- December
- Address
- No. 15, Qiaohe Road, New Taipei City, Taiwan, 235029
- Phone
- 886 2 8912 1200
- Website
- rbcbioscience.com
About RBC Bioscience Corporation
RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis. It offers robotic bench-top workstation for nucleic acid purification under the MagCore Plus II and Giga Automated Nucleic Acid Extractor names; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore EDA Automatic Extraction and Smart PCR Setup, an instrument for nucleic acid extraction and PCR setup pre-treatment. The company also provides NGS, genomic DNA, viral nucleic acids, and total RNA kits. It has operations in Taiwan, rest of Asia, Africa, the United States, and internationally. RBC Bioscience Corporation was founded in 1995 and is based in New Taipei City, Taiwan.
RBC Bioscience Corporation management
5- Mr. Mingwei ZhuoChairman & GM
- Ms. Sulan FangAccountant & Accounting Supervisor
- Mr. Yen-Liang ChenDeputy General Manager of Manufacturing Department & Director
- Mr. Kexin ZhanDeputy General Manager of Management Office
- Mr. Zhengwei WeiDirector of R&D